Heparin Market (Product - Low Molecular Weight Heparin, Unfractionated Heparin, Ultra-low Molecular Weight Heparin; End Applications - Hospitals, Blood and Stem Cell Bank ) - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
Press Release :
Europe Heparin Market: Snapshot
Europe is among the major regions contributing to the global heparin market owing to its developed economy and high prevalence of coagulation disorders. According to the Ageing Report published by the European Commission in 2015, the percentage of population aged above 65 years is expected to increase from 21.0% in 2013 to 32.0% in 2060. Aging is directly proportional to the rising incidence of venous thromboembolism (VTE) diseases such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Hence, the demand for heparin in Europe is expected to increase in the next few years. The heparin market in Europe was valued at US$2.2 bn in 2015 and is projected to expand at a CAGR of 5.2% from 2016 to 2024 to reach US$3.5 bn in 2024.
Heparin Most Widely Used in Hospitals across Europe
Based on end user, the heparin market in Europe has been categorized into hospitals, blood and stem cell banks, and others. Hospitals and clinics widely use heparin as a blood thinner in the treatment of various diseases related to cardiovascular, cancer, and orthopedic. Heparin such as Calcilean, Calciparine, Hepalean, Heparin Leo, and Hepalean-lok are prominently used in hospitals for surgical purposes. The hospitals segment accounted for a major share of the heparin market in Europe as most surgical procedures are often performed in hospitals.
The blood and stem cell banks segment also held a significant share of the market in 2015. Blood and stem cell banks use heparin to collect cord blood and stem cells as heparin promotes the growth of human embryonic stem cells in a defined serum-free medium.
Rapid Growth of Heparin Market Anticipated in Several European Nations
The heparin market in Europe has been segmented on the basis of geography into the following major markets: Germany, France, the U.K., Italy, Spain, Poland, Switzerland, Austria, Hungary, Belgium, Portugal, the Czech Republic, Greece, Slovakia, and Rest of Europe.
Germany accounted for the leading share in the heparin market in Europe in 2015 and is expected to continue its dominance till 2024. Key attributes to the market growth in Germany encompass burgeoning incidence of VTE among patients, resulting in the increased demand for heparin. Moreover, stringent regulations pertaining to Chinese active pharmaceutical ingredients (APIs) due to adulteration issues have attracted new players to the heparin processing and manufacturing business in Europe. Europe has been known to adhere to strict regulations pertaining to the import of heparin. For instance, in 2013, Germany-based meat company, Tönnies GmbH & Co, acquired Pharma Action, a heparin API manufacturer, and proposed to manufacture 30 metric tons of heparin API. Such developments are expected to augment the heparin market’s growth in Germany.
France, Belgium, and Portugal are anticipated to register the highest growth in the coming years. France also held the second position in the heparin market in Europe in 2015. Heparin consumption during and after surgical procedures such as knee replacement, hip surgery, appendectomy, and breast surgery is higher in France as compared to Italy, Spain, and the U.K. The increased risk of thrombosis among the geriatric population is also expected to drive the market for heparin in France.
Major players in the Europe heparin market include Sanofi SA, Pfizer, Inc., Leo Pharma, Teva Pharmaceutical Industries Ltd, and Dr. Reddy’s Laboratories.
This report provides in-depth country wise analysis of the heparin market in Europe. Stakeholders of this report include manufacturers of heparin products, crude heparin suppliers, heparin processing companies, and new players planning to enter the market.
The report provides qualitative and quantitative analysis of the heparin market in Europe. Qualitative analysis comprises market dynamics, trends, product overview, and country-level market information. Quantitative analysis includes market share held by companies in 2015, market size, and forecast for the heparin market in major countries in Europe such as Germany, France, the U.K., Italy, Spain, Poland, Switzerland, Austria, Hungary, Belgium, Portugal, the Czech Republic, Greece, Slovakia, and Rest of Europe from 2014 to 2024. Market revenue is provided in terms of US$ Mn from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 for all the segments, considering 2015 as the base year. The executive summary of the report provides a snapshot of the heparin market in Europe with information on leading segments, country wise market information with respect to the market size, growth rate (CAGR %), and growth factors.
The market overview section comprises impact factors such as drivers, restraints, and opportunities for the heparin market in Europe. These factors would aid the stakeholders in establishing a strong foothold in Europe. Furthermore, the market overview section comprises key industry events, product overview, mortality rate of CVD in Europe, leading causes of death, and country-wise pharmaceutical expenditure. The market attractiveness analysis provides a graphical view comparing the growth and market dynamics in various segments to identify the most attractive market.
Market share analysis is also provided in the competitive landscape section of the report for the year 2015 in terms of value (%). Furthermore, the report analyzes different heparin product types such as unfractionated heparin, low molecular weight heparin, and ultra-low molecular weight heparin. The product type section provides market analysis for different types of heparin in Europe. This includes an overview of product types, indications for use, presence of any biosimilars, market drivers, issues, and regulations amended for its production and use. Prices of products vary based on product type and formulation. Moreover, the heparin market by end-users such as hospitals, blood and stem cell banks, and others has also been analyzed in the report. The report provides average pricing analysis (based on the current prices) to offer an overview of prices of heparin-based pharmaceutical products in the EU (2015 & 2024).
The report provides market analysis for heparin in the major countries in the EU: Germany, France, the U.K., Italy, Spain, Poland, Switzerland, Austria, Hungary, Belgium, Portugal, the Czech Republic, Greece, Slovakia, and Rest of Europe. Market analysis for each of these countries has been provided from 2014 to 2024 along with the CAGR from 2016 to 2024. The market has been estimated for finished heparin formulation and has not considered its APIs. Major factors such as aging population and increasing prevalence of venous thromboembolism (VTE) that propel the market for heparin in Europe are elaborated in the report. This report also covers certain regulations governing the manufacture and import of heparin in some countries.
Major players operating in the heparin market in Europe such as Dr. Reddy's Laboratories Ltd., Leo Pharma, Pfizer, Inc., Sanofi SA, and Teva Pharmaceutical Industries Ltd. are profiled in this report.
The Europe heparin market is segmented into the following categories:
Europe Heparin Market, by Product
- Unfractionated Heparin
- Low Molecular Weight Heparin
- Ultra-low Molecular Weight Heparin
Europe Heparin Market, by End-user
- Blood and Stem Cell Banks
Europe Heparin Market, by Country
- Czech Republic
- Rest of Europe